Miao J, Huang S, Su YR, Lenneman CA, Wright M, Harrell FE, Sawyer DB, Lenihan DJ. Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction.
Biomarkers 2018;
23:704-708. [PMID:
29871526 DOI:
10.1080/1354750x.2018.1485054]
[Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
CONTEXT
Improved left ventricular ejection fraction (LVEF) following administration of recombinant human Neuregulin-1β (NRG), epidermal growth factor (EGF) involved in cardiomyocyte repair/survival, has been observed in patients with systolic heart failure (HF).
METHODS
Serum NRG was measured by ELISA in 248 patients with NYHA class I-IV HF.
RESULTS
NRG exhibited a marginally significant effect on LVEF trajectory over 11 months (p = 0.07). There is no apparent level of NRG that predicts improved survival.
CONCLUSIONS
There is a potential relationship between serum NRG and improved LVEF, indicating the need to investigate the utility of NRG in predicting HF outcomes, including LVEF maintenance.
Collapse